ClinicalTrials.gg
RecruitingNCT07012772Updated Jun 24, 2025

COMBO Endoscopy Oropharyngeal Airway in Sedated Endoscopic Retrograde Cholangiopancreatography for Patients

A Phase 2 interventional study of The COMBO Endoscopy Oropharyngeal Airway in Choledocholithiasis With Cholecystitis With Obstruction, Obstructive Jaundice and Pancreatitis, sponsored by Zhejiang University. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-24.

Sponsored by Zhejiang University · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 4 months later.
Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Hypoxia represents the prevailing adverse occurrence during the sedation of patients undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) with propofol. A recent innovation in this domain is the COMBO Endoscopy Oropharyngeal Airway-a multifaceted device that encompasses capnography monitoring, bite block , oxygenation support, and oropharyngeal airway management. This device has been purposefully designed to cater to the unique requirements of endoscopic procedures. The principal objective of this study is to assess the efficacy of the COMBO Endoscopy Oropharyngeal Airway in reducing the incidence of hypoxia in patients undergoing ERCP under sedation.

02

Conditions studied

  • Choledocholithiasis With Cholecystitis With Obstruction
  • Obstructive Jaundice
  • Pancreatitis
  • Cholelithiasis

Keywords

  • respiratory depression
  • The COMBO Endoscopy Oropharyngeal Airway
  • Hypoxia
  • Sedation
  • ERCP
03

In context

Jaundice, Obstructive

62 studies on the registry are indexed under Jaundice, Obstructive; 15 are open to participants now.

This study's planned enrollment of 50 is below the median of 75 across 40 interventional studies indexed under Jaundice, Obstructive.

Browse Jaundice, Obstructive studies →

Lead sponsor

Zhejiang University is the lead sponsor of 356 studies on the registry; 166 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years;
  • The ranges from I to III.
  • Patients have signed the form.
  • Patients scheduled to undergo sedated ERCP examination;
  • The estimated duration of the procedure does not exceed 45 minutes.

Exclusion criteria

Exclusion Criteria:

  1. Patients with coagulation disorders, tendency for oral/nasal bleeding, mucosal injury/occupying lesions, or difficult oropharyngeal airway insertion making airway management unfeasible;
  2. Severe cardiac dysfunction (\<4 METs);
  3. Severe renal insufficiency (requiring preoperative dialysis);
  4. class C;
  5. Diagnosed (COPD) or other acute/chronic pulmonary diseases requiring long-term/intermittent oxygen therapy;
  6. Increased intracranial pressure;
  7. Upper respiratory tract infections (oral/nasal/pharyngeal);
  8. Fever (core temperature >37.5°C);
  9. Confirmed pregnancy or current breastfeeding;
  10. Allergy to sedatives (e.g., propofol) or medical adhesives;
  11. Emergency procedures;
  12. Multiple trauma injuries;
  13. Peripheral oxygen saturation (SpO2) levels below 95% while breathing room air preoperatively;
  14. \<18.5 or >30 kg/m²;
  15. Current participation in other clinical trials;
  16. Other conditions deemed ineligible by investigators.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    The COMBO Endoscopy Oropharyngeal Airway Group

    In this group, patients use the COMBO Endoscopy Oropharyngeal Airway for oxygenation.

    Device: The COMBO Endoscopy Oropharyngeal Airway

Interventions

  • DeviceThe COMBO Endoscopy Oropharyngeal Airway

    Using the COMBO Endoscopy Oropharyngeal Airway for oxygenation.

06

What researchers measure

Primary outcomes

  1. The incidence of hypoxia

    75% ≤ SpO2 \< 90% for \<60 s

    Time frame: Patients will be followed for the duration of hospital stay, an expected average about 2 hours

Secondary outcomes

  1. The incidence of sub-clinical respiratory depression

    90% ≤ SpO2 \< 95%

    Time frame: Patients will be followed for the duration of hospital stay, an expected average about 2 hours

  2. The incidence of severe hypoxia

    SpO2 \< 75% or 75% ≤ SpO2 \< 90% for ≥60 s

    Time frame: Patients will be followed for the duration of hospital stay, an expected average about 2 hours

Other outcomes

  1. The incidence of other adverse events

    Other adverse events recorded by tools proposed by the World Society of Intravenous Anesthesia International Sedation Task Force

    Time frame: Patients will be followed for the duration of hospital stay, an expected average about 2 hours

07

Study locations

2 of 2 sites recruiting
  • he First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310000, China
    Recruiting
  • The First Affiliated Hospital,Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Sep 2025, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2025
First posted
Jun 10, 2025
StartActual
Jun 12, 2025
Primary completionEst.
Sep 30, 2025
CompletionEst.
Dec 31, 2025
Last update
Jun 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07012772
Responsible party
Diansan Su (Chair of the Department of Anesthesiology, Zhejiang University) — Principal investigator
First posted
Jun 10, 2025
Start date
Jun 12, 2025
Primary completion
Sep 30, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jun 24, 2025

Study contacts

DiSan Head of Anesthesiology, PhD
Contact
184872238@qq.com
86+18616514088
Lianjuan Sun, Master
Contact
sunlianjuan26@163.com
+8618257152767

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion